Feature Channels: Weight Loss

Filters close

Not for public release

This news release is embargoed until 13-Sep-2024 11:00 AM EDT Released to reporters: 11-Sep-2024 11:05 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 13-Sep-2024 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

   
access_time Embargo lifts in 2 days
This news release is embargoed until 18-Sep-2024 12:00 PM EDT Released to reporters: 12-Sep-2024 4:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 18-Sep-2024 12:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Not for public release

This news release is embargoed until 3-Sep-2024 11:00 AM EDT Released to reporters: 29-Aug-2024 11:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 3-Sep-2024 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Nutrition know-how for patients taking anti-obesity medication
Released: 29-Aug-2024 1:05 PM EDT
Nutrition know-how for patients taking anti-obesity medication
UT Southwestern Medical Center

Since anti-obesity medications have become more widely known and prescribed, they have been touted as game-changing treatments for chronic overweight and obesity. But one common misconception about these medications is that they’re a magic bullet for better health, and it doesn’t necessarily matter what you eat when you’re taking them.

Released: 28-Aug-2024 12:30 PM EDT
Primary Care Providers Urged to Assist Patients Who Engage in Emotional Eating
Wolters Kluwer Health: Lippincott

Primary care providers are well positioned to address emotional eating because of their long-term relationships with patients, noted Jana DeSimone Wozniak, PhD and Hsiang Huang, MD, MPH, of Harvard Medical School and Cambridge Health Alliance in Cambridge, Massachusetts.

Not for public release

This news release is embargoed until 26-Aug-2024 5:00 PM EDT Released to reporters: 20-Aug-2024 2:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 26-Aug-2024 5:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Five Common Myths About Weight Loss
Released: 26-Aug-2024 3:05 PM EDT
Five Common Myths About Weight Loss
University of Utah Health

Popular ideas about weight loss often aren’t based in science and can actively harm your health. Here are some of the most common myths, along with some tips to improve your health sustainably while maintaining a healthy attitude toward weight and food.

Released: 22-Aug-2024 7:05 AM EDT
First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity
Palatin Technologies, Inc.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that patient dosing has started for the clinical study entitled: BMT-801: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity (ClinicalTrials.gov Identifier: NCT06565611).

Released: 20-Aug-2024 10:30 AM EDT
How do GLP-1 weight loss drugs affect the liver?
Michigan Medicine - University of Michigan

Drugs such as Ozempic, Rybelsus and Wegovy have made news for their abilities to treat diabetes and encourage weight loss. To give a clearer understanding of the benefits and risks of GLP-1 agonists for patients with liver disease, Robert Fontana, M.D., a Michigan Medicine hepatologist, answered our questions.

Released: 20-Aug-2024 7:00 AM EDT
Combining Two Diabetes Drugs Helps Promote Weight Loss and Blood Sugar Control
American Physiological Society (APS)

New research finds a combination of drugs improves weight loss, glucose control and insulin resistance better than either drug alone. Using two diabetes medications together, such as a semaglutide like Ozempic or Rybelsus, with a second, newer class of drug, may offer a noninvasive solution to help people with Type 2 diabetes lose weight and manage their condition without the need for bariatric surgery.

Newswise:Video Embedded one-size-does-not-fit-all
VIDEO
Released: 7-Aug-2024 10:05 AM EDT
One Size Does Not Fit All
Cedars-Sinai

A new class of medications called GLP-1s (glucagon-like peptide-1 receptor agonists) have been grabbing headlines for their dramatic results in helping people shed stubborn pounds, thereby controlling diabetes as well as reducing their risk of heart disease.

Newswise: Navigating a weight loss journey
Released: 5-Aug-2024 4:05 PM EDT
Navigating a weight loss journey
Michigan Medicine - University of Michigan

One patient details her success story losing weight through this individualized approach

Released: 30-Jul-2024 2:05 PM EDT
أسئلة وأجوبة من مايو كلينك: دعم أدوية إنقاص الوزن بالتغذية الكافية والمخصصة
Mayo Clinic

تقدم تارا شمت، اختصاصية النُّظم الغذائية المسجَّلة في مايو كلينك في مدينة روتشستر، ولاية مينيسوتا، معلومات قيمة حول سبب أهمية الحديث عن التغذية في سياق أدوية إنقاص الوزن.

Released: 30-Jul-2024 2:05 PM EDT
Perguntas e Respostas da Mayo Clinic: Apoiar medicamentos para perda de peso com nutrição adequada e personalizada
Mayo Clinic

Tara Schmidt, nutricionista registrada na Mayo Clinic em Rochester, Minnesota, fornece informações sobre a importância de se discutir nutrição no contexto de medicamentos para a perda de peso.

Not for public release

This news release is embargoed until 29-Jul-2024 5:00 PM EDT Released to reporters: 23-Jul-2024 12:15 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 29-Jul-2024 5:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 29-Jul-2024 2:05 PM EDT
Professors Weigh In on the Obesity Breakthrough of Ozempic and Similar Drugs
Rutgers University-New Brunswick

New medications and holistic approaches offer hope in the battle against obesity, say Rutgers Health experts.

Newswise: The Medical Minute: What to know about Ozempic and weight loss drugs
Released: 10-Jul-2024 11:05 AM EDT
The Medical Minute: What to know about Ozempic and weight loss drugs
Penn State Health

Weight-loss drugs are all over the news these days. A Penn State Health expert helps separate fact from fiction and determine what’s the safest alterative for the people who need them.

Newswise: Monell Center Discovery Could Help Reduce Adverse Side Effects of Popular Next-generation Obesity Medications
8-Jul-2024 8:05 AM EDT
Monell Center Discovery Could Help Reduce Adverse Side Effects of Popular Next-generation Obesity Medications
Monell Chemical Senses Center

By teasing apart the therapeutic benefits from the adverse effects of new-generation obesity medications, researchers from the Monell Chemical Senses Center found a population of neurons in the brain that controls food intake without causing nausea in an animal model.



close
2.94008